Ping Chen

US Patent:

20140080884, Mar 20, 2014

Filed:

Jun 25, 2012

Appl. No.:

14/118998

Inventors:

Itzia Arroyo - Union NJ, US
Davida Krueger - Brooklyn NY, US
Ping Chen - Edison NJ, US
Aaron Moment - Middletown NJ, US
Tesfaye Biftu - Freehold NJ, US
Faye Sheen - Hoddesdon, GB
Yanfeng Zhang - Panan, Zhejiang, CN

Assignee:

Merck Sharp & Dohme Ltd. - Hoddesdon, Hertfordshire
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04

US Classification:

514407, 5483605

Abstract:

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

US Patent:

20230008022, Jan 12, 2023

Filed:

Nov 25, 2019

Appl. No.:

17/295497

Inventors:

Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.